 CRISPR Therapeutics NASDAQ: CRSP presented results from its ongoing Phase 1 COBALT-LYM CTX130 exa-cel trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies. CTX130 was well tolerated across all dose levels. 